 |
| Anno I | Numero 8 | Dicembre 2016 |
| Comitato scientifico editoriale: Sergio Bracarda, Giacomo Cartenì, Giuseppe Procopio Editore: Intermedia – Direttore Responsabile: Mauro Boldrini |
| Notizie dalla ricerca |
The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma |
| Sequential targeted therapies are the standard of care for patients with metastaticrenal cell carcinoma (mRCC). Several drugs are available for patients whose disease progresses while they receive initial tyrosine kinase inhibitor (TKI) therapy; these include nivolumab (an inhibitor of PD-1 receptor), everolimus (an inhibitor of the mechanistic target of rapamycin) or additional TKIs. Until now, there has been no clinical evidence to support the use of one strategy versus another, so investigators and physicians rely on … |
| Continua a leggere |
| The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis |
| To systematically evaluate the overall efficacy and safety of current anti-PD-1/PD-L1 antibodies for treatment of patients with advanced or refractory cancer. Fifty-one trials including 6,800 patients were included. The overall response rates for melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) were 29% (95% CI: 1.53-2.41), 21% (95% CI: 17%-25%) and 21% (95% CI: 16%-27%) respectively. While the overall adverse effects rate for melanoma, NSCLC, RCC were 16% … |
| Continua a leggere |
| Recent advances in immuno-oncology and its application to urological cancers |
| Recent advances in immuno-oncology have the potential to transform the practice of medical oncology. Antibodies directed against negative regulators of T-cell function (checkpoint inhibitors), engineered cell therapies and innate immune stimulators, such as oncolytic viruses, are effective in a wide range of cancers. Immune'based therapies have had a clinically meaningful impact on the treatment of advanced melanoma, and the lessons regarding use of single agents and combinations in melanoma may be … |
| Continua a leggere |
| Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment |
| Cancer immunotherapy has been a subject of intense research over the last several years, leading to new approaches for modulation of the immune system to treat malignancies. Immune checkpoint inhibitors (anti-CLTA-4 antibodies and anti-PD-1/PD-L1antibodies) potentiate the host's own antitumor immune response. These immune checkpoint inhibitors have shown impressive clinical efficacy in advanced melanoma, metastatic kidney cancer, and metastatic non-small cell lung cancer … |
| Continua a leggere |
| Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma |
| In the past decade, several agents targeting angiogenesis and signal transduction pathways have replaced the use of cytokines as standard of care treatment for metastatic renal cell carcinoma (RCC) after showing improved clinical benefit and survival. Currently, several novel immunotherapy agents targeting the programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) pathways are being tested in metastatic RCC and are bound to revolutionise the management of … |
| Continua a leggere |
| Appuntamenti AIOM |
| IV Young Specialist Renal Care |
| Bologna, 13 – 14 gennaio 2017 |
| Aggiornamenti in Oncologia: iponatriemia |
| Verona, 26 – 27 gennaio 2017 |
| Questi e altri appuntamenti si possono consultare sul sito AIOM www.aiom.it |
| Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001 Per contattare la redazione e commentare le notizie clicca qui: redazione Per consultare i numeri arretrati della newsletter clicca qui: archivio Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI |
Questo progetto è stato realizzato con il contributo di  |